Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Zika: WHO evaluates mosquito controls
aedes mosquito
Zika outbreaks are thought to be linked to serious birth defects and a rise in cases of
Guillain-Barré syndrome.
Release of sterile mosquitoes among possibilities 

The World Health Organisation (WHO) is evaluating a suite of new methods to control mosquito populations in a bid to tackle Zika virus, which is primarily spread by the Aedes aegypti mosquito.

Current possibilities include the introduction of genetically modified mosquitoes, or sterile male insects to suppress the population.

Zika was recently declared a global health emergency as it spread across the Americas. The outbreaks are thought to be linked to serious birth defects and a rise in cases of the autoimmune disorder, Guillain-Barré syndrome, though this has not yet been scientifically proven.

While 15 groups are currently working to develop a vaccine, WHO predicts it could take at least 18 months before large-scale trials can take place. With this in mind, the organisation is recommending better mosquito control as the best line of defence.

WHO has convened a vector control advisory group to consider new tools, including GM mosquitoes, which have previously been trialled in the Cayman Islands resulting in a significant decline in mosquito populations.

The group is backing further field trials and risk assessment to look into the potential impact on disease transmission.

Another strategy being developed is the release of sterile male insects so that when females mate with them, their eggs are not viable and the insect population dies out.

The release of males carrying the naturally occurring Wolbachia bacteria is another option. The bacteria does not affect humans or other mammals but prevents mosquito eggs hatching when females mate with affected males.

A different strain reduces the insect's capacity to spread dengue virus. Mosquitoes carrying the bacteria have already been released in a number of places, including Australia, Brazil, Indonesia and Vietnam as part of dengue control programmes. Large-scale field trials are expected to begin soon.

Meanwhile, WHO advocates the elimination of mosquito breeding sites as an effective intervention, as well as the use of insect repellents.

For more of the WHO's guidance, see: http://www.who.int/emergencies/zika-virus/articles/mosquito-control/en/

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.